ArticleNeuropsychiatric disease and treatment2026
Second-Generation Long-Acting Injectable Antipsychotics: A Comprehensive Assessment of Effectiveness, Safety, and Cost.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Distinguishing Perception from Evidence in Psychiatrists' Attitudes Toward Second-Generation Long-Acting Injectable Antipsychotics [Letter].Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Second-generation long-acting injectable antipsychotics (SG-LAIs) improve adherence, reduce relapse, and enhance outcomes in schizophrenia, yet remain underused. In Romania, data on psychiatrists' views is limited. Objective: To assess Romanian psychiatrists' attitudes and prescribing behaviors regarding SG-LAIs, and identify key drivers and barriers to their use. Methods: We conducted a cross-sectional questionnaire survey among psychiatrists in urban hospital, outpatient, and private settings, treating more than 1,000 patients with schizophrenia. The survey rated the four SG-LAIs available in Romania (aripiprazole, olanzapine, paliperidone, and risperidone) on efficacy, tolerability, dosing flexibility, monitoring needs, prescribing frequency, and perceived obstacles/facilitators. Results: 80 psychiatrists participated. Aripiprazole LAI received the most favorable ratings, ranking highest for efficacy, safety, patient functioning, ease of administration, guideline alignment, side-effect profile, monitoring requirements, and overall preference. Paliperidone and risperidone were also positively evaluated for dosing versatility, whereas olanzapine generally scored lowest. Main factors encouraging LAI prescription were improved adherence (96.3%) and reduced relapse risk (96.3%), followed by a favorable clinical profile (66.3%). Key barriers included lack of patient trust (57.5%), lack of hospital supply (43.8%), absence of LAI formulations for certain antipsychotics (43.8%), and limited experience (36.3%). Conclusion: Romanian psychiatrists show a strong preference for aripiprazole LAI, with decisions driven mainly by clinical benefits. Reducing patient concerns and system-level limitations-especially availability, indications, and communication- may support increased use of SG-LAIs in everyday clinical care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.